Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784 · RASolve 301 Phase 3Recruiting
- Lead sponsor
- Revolution Medicines, Inc. (Industry)
- Enrollment
- 590 (estimated)
- Start date
- 6 May 2025
- Primary completion
- 1 Dec 2027 (estimated)
- Study completion
- 1 Dec 2030
- Last update posted
- 29 Sep 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 2
Interventions
- daraxonrasib Drug
- docetaxel Drug
Conditions and primary outcome
- NSCLC (Non-small Cell Lung Cancer)
- Non-Small Cell Lung Cancer
- NSCLC
- NSCLC (Non-small Cell Lung Carcinoma)
- NSCLC (Advanced Non-small Cell Lung Cancer)
Primary outcome
Progression free survival (PFS) per Blinded Independent Central Review (BICR) in the RAS G12X-C population (i.e RAS G12X excluding G12C) (Up to approximately 4 years); Overall survival (OS) in the RAS G12X-C population (Up to approximately 4 years)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06881784.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06881784 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.